Company news
Ac Immune Sa (NASDAQ:ACIU) news
Ac Immune Sa news releases on 6ix. Latest, Feb 8, 2021: AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease
Press releases — page 3
AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease
February 7, 2021
AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway
January 28, 2021
AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay
December 14, 2020
Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directors
November 19, 2020
Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer
November 17, 2020
AC Immune Reports Q3 2020 Financial Results and Provides Business Update
November 12, 2020
AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development
November 8, 2020
Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent
October 8, 2020
AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease
September 22, 2020
AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020
AC Immune Reports Q2 2020 Financial Results and Provides Business Update
August 4, 2020
AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration
August 2, 2020
AC Immune Wins Prestigious Award to Develop a “Game-Changing” Parkinson’s Diagnostic Tool
July 29, 2020
AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent
July 27, 2020
AC Immune Advances phospho-Tau Alzheimer’s Vaccine in Phase 1b/2a Study
July 15, 2020
AC Immune Announces Results of Annual General Meeting
June 25, 2020
AC Immune Reports Q1 2020 Financial Results and Provides Business Update
May 3, 2020
AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook
March 29, 2020
AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership
March 22, 2020
AC Immune Q3 2019 Financial Results and Business Update
November 12, 2019
AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program
September 19, 2019
AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620
September 16, 2019